1. Denborough MA, Lovell RRH. Anaesthetic deaths in a family. Lancet. 1960;276(7140):45-46.
2. Glahn KPE, Bendixen D, Girard T, et al. Availability of dantrolene for the management of malignant hyperthermia crises: European Malignant Hyperthermia Group guidelines. Br J Anaesth. 2020;125(2):133-140. doi: 10.1016/j.bja.2020.04.089
3. Rosenberg H, Pollock N, Schiemann A, et al. Malignant hyperthermia: a review. Orphanet J Rare Dis. 2015;10:93. doi:10.1186/s13023-015-0310-1
4. Glahn KPE, Girard T, Hellblom A, et al. Recognition and management of a malignant hyperthermia crisis: updated 2024 guideline from the European Malignant Hyperthermia Group. Br J Anaesth. 2025;134(1): 221-223, doi:10.1016/j.bja.2024.09.022
5. Schneiderbanger D, Johannsen S, Roewer N, et al. Management of malignant hyperthermia: diagnosis and treatment. Ther Clin Risk Manag. 2014;10:355-362. doi:10.2147/tcrm.S47632
6. Group EMH. European Malignant Hyperthermia Group. 2015. Available from: http://www.emhg.org [Last Accessed; 10 July 2015].
7. Wolvetang T, Hofland J, Takkenberg H. Knowledge on malignant hyperthermia: as rare as the disease? A nation wide survey. BMC Anesthesiol. 2014;14(1):A18. doi:10.1186/1471-2253-14-S1-A18
8. Monzani R, Alampi D, Bignami E, et al. National insights on malignant hyperthermia: a SIAARTI survey on clinical practices, preparedness, and future directions. J Anesth Analg Crit Care. 2025;5(1):85. doi:10.1186/s44158-025-00293-4
9. Wang J, Yu Y, Gao Y, et al. The anesthesiologists' perception of malignant hyperthermia and availability of dantrolene in China: a cross-sectional survey. Risk Manag Healthc Policy. 2024;17:763-773. doi:10.2147/rmhp.S454895
10. Tan L, Yu H, Yan J, et al. The knowledge profile, competence and pending problems of Chinese anesthesiologists in dealing with malignant hyperthermia: a cross-sectional survey. J Multidiscip Healthc. 2023;16: 133-142. doi:10.2147/jmdh.S387025
11. Larach MG, Brandom BW, Allen GC, et al. Malignant hyperthermia deaths related to inadequate temperature monitoring, 2007-2012: a report from the North American malignant hyperthermia registry of the malignant hyperthermia association of the United States. Anesth Analg. 2014;119(6):1359-1366. doi:10.1213/ane.0000000000000421
12. Hopkins PM. Malignant hyperthermia: advances in clinical management and diagnosis. Br J Anaesth. 2000;85(1):118-128. doi:10.1093/bja/85.1.118
13. Glahn KPE, Girard T, Hellblom A, et al. Recognition and management of a malignant hyperthermia crisis: updated 2024 guideline from the European Malignant Hyperthermia Group. Br J Anaesth. 2025;134(1): 221-223. doi:10.1016/j.bja.2024.09.022